Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement
Purpose: To explore molecular alterations and their correlation with the survival of patients with glioblastoma (GBM) with corpus callosum (CC) involvement (ccGBM).Methods: Electronic medical records were reviewed for glioma patients tested for molecular alterations and treated at our hospital betwe...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2021.701426/full |
| _version_ | 1819090323872153600 |
|---|---|
| author | Meng Cui Meng Cui Xin Gao Xin Gao Yihong Chi Meng Zhang Meng Zhang Hepu Lin Hewen Chen Hewen Chen Caihong Sun Xiaodong Ma Xiaodong Ma |
| author_facet | Meng Cui Meng Cui Xin Gao Xin Gao Yihong Chi Meng Zhang Meng Zhang Hepu Lin Hewen Chen Hewen Chen Caihong Sun Xiaodong Ma Xiaodong Ma |
| author_sort | Meng Cui |
| collection | DOAJ |
| description | Purpose: To explore molecular alterations and their correlation with the survival of patients with glioblastoma (GBM) with corpus callosum (CC) involvement (ccGBM).Methods: Electronic medical records were reviewed for glioma patients tested for molecular alterations and treated at our hospital between January 2016 and July 2020. ccGBM was compared to GBM without CC involvement (non-ccGBM) to identify differences in molecular alterations. Clinical outcomes and survival were compared between ccGBM and non-ccGBM patients, as well as among patients with ccGBM with different molecular alteration statuses. ccGBM was also compared to diffuse midline glioma (DMG) to clarify their correlation in molecular alterations, the progression-free survival (PFS), and overall survival (OS).Results: Thirty ccGBM and 88 non-ccGBM patients were included. PDGFRA amplification (PDGFRAamp, 33.3 vs. 9.1%, P = 0.004) and missense mutation (PDGFRAmut, 20.0 vs. 3.4%, P = 0.011) both had higher incidences in ccGBM than in non-ccGBM. PDGFRA alteration was associated with the occurrence of ccGBM (OR = 4.91 [95% CI: 1.55–15.52], P = 0.007). ccGBM with PDGFRAamp resulted in a shorter median PFS (8.6 vs. 13.5 months, P = 0.025) and OS (12.4 vs. 17.9 months, P = 0.022) than non-ccGBM with PDGFRAnon-amp. ccGBM with PDGFRAamp combined with PDGFRAmut (PDGFRAamp-mut) had a shorter median PFS (7.6 vs. 8.9 months, P = 0.022) and OS (9.6 vs. 17.8 months, P = 0.006) than non-ccGBM with wild-type PDGFRA and no amplification (PDGFRA-w, non-amp). Compared to ccGBM with PDGFRA-w, non-amp, ccGBM with PDGFRAamp and PDGFRAamp-mut both had a shorter median PFS and OS (P < 0.05). The hazard ratios (HRs) of PDGFRAamp for PFS and OS in ccGBM were 3.08 (95% CI: 1.02–9.35, P = 0.047) and 5.07 (1.52–16.89, P = 0.008), respectively, and the HRs of PDGFRAamp-mut for PFS and OS were 13.16 (95% CI: 3.19–54.40, P < 0.001) and 16.36 (2.66–100.70, P = 0.003). ccGBM may have similar incidences of PDGFRAamp or mut (PDGFRAamp/mut) as DMG, and they also had similar median PFS (10.9 vs. 9.0 months, P = 0.558) and OS (16.8 vs. 11.5 months, P = 0.510).Conclusion:PDGFRA alterations are significantly associated with the occurrence and poor prognosis of ccGBM. ccGBM with PDGFRAamp/mut may be classified as a single subtype of GBM that has a similar survival rate to DMG. PDGFR inhibitors may be a promising treatment method for ccGBM. |
| first_indexed | 2024-12-21T22:22:01Z |
| format | Article |
| id | doaj.art-b992d3fea3fd48e9825b33bc9107c05f |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-21T22:22:01Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-b992d3fea3fd48e9825b33bc9107c05f2022-12-21T18:48:19ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2021-07-011510.3389/fnins.2021.701426701426Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum InvolvementMeng Cui0Meng Cui1Xin Gao2Xin Gao3Yihong Chi4Meng Zhang5Meng Zhang6Hepu Lin7Hewen Chen8Hewen Chen9Caihong Sun10Xiaodong Ma11Xiaodong Ma12Medical School of Chinese PLA, Beijing, ChinaDepartment of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, ChinaDepartment of Information Technology, Xian Janssen Pharmaceutical Ltd., Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The Seventh Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, ChinaPurpose: To explore molecular alterations and their correlation with the survival of patients with glioblastoma (GBM) with corpus callosum (CC) involvement (ccGBM).Methods: Electronic medical records were reviewed for glioma patients tested for molecular alterations and treated at our hospital between January 2016 and July 2020. ccGBM was compared to GBM without CC involvement (non-ccGBM) to identify differences in molecular alterations. Clinical outcomes and survival were compared between ccGBM and non-ccGBM patients, as well as among patients with ccGBM with different molecular alteration statuses. ccGBM was also compared to diffuse midline glioma (DMG) to clarify their correlation in molecular alterations, the progression-free survival (PFS), and overall survival (OS).Results: Thirty ccGBM and 88 non-ccGBM patients were included. PDGFRA amplification (PDGFRAamp, 33.3 vs. 9.1%, P = 0.004) and missense mutation (PDGFRAmut, 20.0 vs. 3.4%, P = 0.011) both had higher incidences in ccGBM than in non-ccGBM. PDGFRA alteration was associated with the occurrence of ccGBM (OR = 4.91 [95% CI: 1.55–15.52], P = 0.007). ccGBM with PDGFRAamp resulted in a shorter median PFS (8.6 vs. 13.5 months, P = 0.025) and OS (12.4 vs. 17.9 months, P = 0.022) than non-ccGBM with PDGFRAnon-amp. ccGBM with PDGFRAamp combined with PDGFRAmut (PDGFRAamp-mut) had a shorter median PFS (7.6 vs. 8.9 months, P = 0.022) and OS (9.6 vs. 17.8 months, P = 0.006) than non-ccGBM with wild-type PDGFRA and no amplification (PDGFRA-w, non-amp). Compared to ccGBM with PDGFRA-w, non-amp, ccGBM with PDGFRAamp and PDGFRAamp-mut both had a shorter median PFS and OS (P < 0.05). The hazard ratios (HRs) of PDGFRAamp for PFS and OS in ccGBM were 3.08 (95% CI: 1.02–9.35, P = 0.047) and 5.07 (1.52–16.89, P = 0.008), respectively, and the HRs of PDGFRAamp-mut for PFS and OS were 13.16 (95% CI: 3.19–54.40, P < 0.001) and 16.36 (2.66–100.70, P = 0.003). ccGBM may have similar incidences of PDGFRAamp or mut (PDGFRAamp/mut) as DMG, and they also had similar median PFS (10.9 vs. 9.0 months, P = 0.558) and OS (16.8 vs. 11.5 months, P = 0.510).Conclusion:PDGFRA alterations are significantly associated with the occurrence and poor prognosis of ccGBM. ccGBM with PDGFRAamp/mut may be classified as a single subtype of GBM that has a similar survival rate to DMG. PDGFR inhibitors may be a promising treatment method for ccGBM.https://www.frontiersin.org/articles/10.3389/fnins.2021.701426/fullglioblastomacorpus callosumPDGFRA amplificationPDGFRA mutationsurvival |
| spellingShingle | Meng Cui Meng Cui Xin Gao Xin Gao Yihong Chi Meng Zhang Meng Zhang Hepu Lin Hewen Chen Hewen Chen Caihong Sun Xiaodong Ma Xiaodong Ma Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement Frontiers in Neuroscience glioblastoma corpus callosum PDGFRA amplification PDGFRA mutation survival |
| title | Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement |
| title_full | Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement |
| title_fullStr | Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement |
| title_full_unstemmed | Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement |
| title_short | Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement |
| title_sort | molecular alterations and their correlation with the survival of glioblastoma patients with corpus callosum involvement |
| topic | glioblastoma corpus callosum PDGFRA amplification PDGFRA mutation survival |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2021.701426/full |
| work_keys_str_mv | AT mengcui molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT mengcui molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT xingao molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT xingao molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT yihongchi molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT mengzhang molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT mengzhang molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT hepulin molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT hewenchen molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT hewenchen molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT caihongsun molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT xiaodongma molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement AT xiaodongma molecularalterationsandtheircorrelationwiththesurvivalofglioblastomapatientswithcorpuscallosuminvolvement |